Bellicum Pharmaceuticals Inc logo

Bellicum Pharmaceuticals Inc

OTCPK:BLCM (USA)  
$ 0.07 0 (0%) 02:59 PM EST
At Loss
Market Cap:
$ 726.00K
Enterprise V:
$ -45.43M
Volume:
-
Avg Vol (2M):
20.86K
Also Trade In:
Volume:
-
At Loss
Avg Vol (2M):
20.86K

Business Description

Bellicum Pharmaceuticals Inc logo
Bellicum Pharmaceuticals Inc
NAICS : 325412 SIC : 2834
ISIN : US0794811077
Description
Bellicum Pharmaceuticals Inc is a biopharmaceutical company that has discovered and developed novel, controllable cellular immunotherapies for various forms of cancer, including both hematological cancers and solid tumors. its proprietary Chemical Induction of Dimerization technology platform is designed to enable control of components of the immune system in real-time. Its product candidates are; BPX-601 an autologous GoCAR-T product candidate designed to treat solid tumors expressing prostate stem cell antigen, or PSCA, and BPX-603 an autologous dual-switch GoCAR-T product candidate designed to target solid tumors that express the human epidermal growth factor receptor 2 antigen, or HER2.

Financial Strength

Name Current Vs Industry Vs History
Cash-To-Debt No Debt
Equity-to-Asset -3.94
Interest Coverage No Debt
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -130.6
Distress
Grey
Safe
WACC vs ROIC
WACC
ROIC

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 35.14
9-Day RSI 39.8
14-Day RSI 40.84
6-1 Month Momentum % -74.97
12-1 Month Momentum % -90.55

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 3.04
Quick Ratio 3.04
Cash Ratio 2.63
Days Sales Outstanding 82.54

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -19.8

Profitability Rank

Name Current Vs Industry Vs History
Operating Margin % -1579.97
Net Margin % -1483.95
FCF Margin % -1515.98
ROA % -127.22
ROIC % -2891.5
ROC (Joel Greenblatt) % -133853.93
ROCE % -175.23

GF Value Rank

Name Current Vs Industry Vs History
PS Ratio 1.56
EV-to-EBIT 1.91
EV-to-EBITDA 1.91
EV-to-Revenue -30.13
EV-to-FCF 1.99
Earnings Yield (Greenblatt) % 52.36
FCF Yield % -3148.9

Financials

BLCM's 30-Y Financials
Income Statement Breakdown
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with OTCPK:BLCM

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Bellicum Pharmaceuticals Inc Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 1.508
EPS (TTM) ($) -0.72
Beta 1.01
Volatility % 167.19
14-Day RSI 40.84
14-Day ATR ($) 0.016471
20-Day SMA ($) 0.085353
12-1 Month Momentum % -90.55
52-Week Range ($) 0.06 - 1.31
Shares Outstanding (Mil) 9.72

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Bellicum Pharmaceuticals Inc Filings

Filing Date Document Date Form
No Filing Data

Bellicum Pharmaceuticals Inc Stock Events

Financials Calendars
Event Date Price($)
No Event Data

Bellicum Pharmaceuticals Inc Frequently Asked Questions

What is Bellicum Pharmaceuticals Inc(BLCM)'s stock price today?
The current price of BLCM is $0.07. The 52 week high of BLCM is $1.31 and 52 week low is $0.06.
When is next earnings date of Bellicum Pharmaceuticals Inc(BLCM)?
The next earnings date of Bellicum Pharmaceuticals Inc(BLCM) is .
Does Bellicum Pharmaceuticals Inc(BLCM) pay dividends? If so, how much?
Bellicum Pharmaceuticals Inc(BLCM) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1